Core Viewpoint - Reap Bio (300119) reported a significant increase in revenue and net profit for the first half of 2025, driven by the growth in sales of veterinary biological products and improved gross margin contributions [1] Financial Performance - The company achieved an operating revenue of 1.708 billion yuan, representing a year-on-year growth of 20.53% [1] - The net profit attributable to shareholders reached 257 million yuan, marking a year-on-year increase of 57.59% [1] - Basic earnings per share were reported at 0.56 yuan [1] Business Segments - The sales proportion of veterinary biological products has been continuously increasing, contributing significantly to the overall performance growth [1] - The improvement in comprehensive gross margin has also played a crucial role in enhancing the company's financial results [1]
瑞普生物:上半年净利润2.57亿元 同比增长57.59%